The article reviews recent advances in the targeted treatment of gynecologic malignancies, focusing on immunotherapy and antibody-drug conjugates (ADCs). It highlights the development and clinical efficacy of novel therapeutic agents, such as immune checkpoint inhibitors (ICIs) and ADCs, in managing cervical, endometrial, and ovarian cancers. Key advancements include the FDA approval of pembrolizumab for advanced or recurrent endometrial and cervical cancers, dostarlimab for dMMR/MSI-H recurrent endometrial cancer, and the approval of Tisotumab Vedotin (TV) and Trastuzumab Deruxtecan (T-DXd) for cervical cancer. The article also discusses the ongoing trials and data supporting these approvals, emphasizing the potential of these treatments to improve patient outcomes.The article reviews recent advances in the targeted treatment of gynecologic malignancies, focusing on immunotherapy and antibody-drug conjugates (ADCs). It highlights the development and clinical efficacy of novel therapeutic agents, such as immune checkpoint inhibitors (ICIs) and ADCs, in managing cervical, endometrial, and ovarian cancers. Key advancements include the FDA approval of pembrolizumab for advanced or recurrent endometrial and cervical cancers, dostarlimab for dMMR/MSI-H recurrent endometrial cancer, and the approval of Tisotumab Vedotin (TV) and Trastuzumab Deruxtecan (T-DXd) for cervical cancer. The article also discusses the ongoing trials and data supporting these approvals, emphasizing the potential of these treatments to improve patient outcomes.